Overview

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Investigators seek a new therapeutic strategy for castrated resistant prostate cancer(CRPC) patients with PI3K-AKT-mTOR signaling pathway deficiency by next generation sequencing(NGS).
Phase:
Phase 3
Details
Lead Sponsor:
Tianjin Medical University Second Hospital
Collaborators:
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicineļ¼ŒChina
Tianjin First Central Hospital
Tianjin Medical University General Hospital
Treatments:
Everolimus
Sirolimus